Business Context and Reporting Period
Company: CURIS, INC.
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2007
Business Overview: Curis is a drug discovery and development company focused on leveraging signaling pathway technologies to create targeted medicines, primarily for cancer, neurological, and cardiovascular diseases. The company operates in a single segment: developmental biology products. It has never been profitable and relies on strategic collaborations, license fees, and equity financing to fund operations.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2007 | Nine Months Ended Sep 30, 2007 | Balance Sheet (Sep 30, 2007) |
|---|---|---|---|
| Net Revenues | $1,312,202 | $4,903,712 | N/A |
| Net Loss | $(3,718,300) | $(11,256,617) | N/A |
| Loss Per Share (Basic/Diluted) | $(0.06) | $(0.22) | N/A |
| Cash and Cash Equivalents | N/A | N/A | $17,881,406 |
| Marketable Securities | N/A | N/A | $23,208,689 |
| Total Current Assets | N/A | N/A | $41,821,584 |
| Total Current Liabilities | N/A | N/A | $4,187,786 |
| Debt (Current Portion) | N/A | N/A | $714,377 |
| Debt (Long-Term) | N/A | N/A | $0 |
| Accumulated Deficit | N/A | N/A | $(700,140,112) |
Cash Flow (Nine Months Ended Sep 30, 2007):
- Net cash used in operating activities: $(9,175,960)
- Net cash used in investing activities: $(5,092,369)
- Net cash provided by financing activities: $13,320,403
Material Changes vs. Prior Period
- Revenue Decline: Net revenues decreased 69% for the three months ended September 30, 2007, compared to the same period in 2006. This was driven by the conclusion of research funding under collaborations with Genentech (Hedgehog antagonist and Wnt signaling), Centocor, and the Spinal Muscular Atrophy Foundation. License fee revenue also dropped significantly due to the absence of a $2.28 million settlement payment from Micromet recognized in the prior year.
- Expense Reduction: Research and development expenses decreased 13% year-over-year for the nine-month period, primarily due to the termination of funded programs. However, spending on internal "Targeted Cancer Drug Development Platform" programs (including CUDC-101) increased significantly, offsetting declines in collaborator-funded work.
- Asset Impairments: The company recorded $347,000 in property and equipment impairment charges and a $145,000 write-down of an investment in ES Cell International (ESI) during the nine-month period.
- Collaboration Terminations: Procter & Gamble notified Curis of its intent to terminate their collaboration effective November 2007. Ortho Biotech terminated its license agreement in August 2007.
Guidance, Outlook, and Risks
- Outlook: Management expects to incur significant operating losses for the foreseeable future. The company anticipates that existing capital resources, combined with a recent $3 million milestone payment from Genentech (received in October 2007) and continued funding from Wyeth, will sustain operations into mid-2009.
- Development Pipeline: Curis plans to file an Investigational New Drug (IND) application for its lead candidate, CUDC-101, in the first quarter of 2008, with Phase I clinical trials expected to begin in the second quarter of 2008. The company is actively seeking a corporate collaboration for CUDC-101.
- Financing: In August 2007, Curis completed a private placement raising approximately $14.4 million in net proceeds. The company may need to raise additional funds through equity or debt offerings, which could result in dilution.
- Risks:
- Liquidity: Dependence on collaborations for revenue and the need for additional financing to fund internal R&D.
- Regulatory: Uncertainty regarding FDA approval timelines and the success of preclinical and clinical trials.
- Stock Price: The company's stock price has recently traded below the $1.00 minimum bid price required for continued listing on the Nasdaq Global Market, posing a risk of delisting.
- Restatement History: The company previously restated financial results for 2003-2005 due to accounting errors, creating potential litigation risks.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $41 million in liquid assets (cash and marketable securities) to fund operations through mid-2009, considering the high burn rate of internal R&D.
- Collaboration Milestones: Monitor the status of the Genentech Phase I expansion cohort and the potential for future contingent payments, as well as the status of the Wyeth collaboration.
- IND Filing Timeline: Confirm the filing of the IND for CUDC-101 in Q1 2008 and the subsequent initiation of clinical trials.
- Nasdaq Compliance: Track the stock price to ensure it meets the $1.00 minimum bid price requirement to avoid delisting from the Nasdaq Global Market.
- Debt Covenants: Review compliance with the working capital ratio covenant required by the Boston Private Bank & Trust Company loan agreements.